Vistagen’s Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study
Vistagen shares plunge after its Phase 3 fasedienol trial for social anxiety failed to meet the primary endpoint, despite favorable safety data.
‘Military To Start Testing Service Members For The Psychedelic Psilocin, Memo Shows’ – Marijuana Moment
https://www.marijuanamoment.net/military-to-start-testing-service-members-for-the-psychedelic-psilocin-memo-shows/
Altamira Therapeutics’ SemaPhore Delivery Platform Shows Significant Synergis-tic Effects Of ZBTB46 mRNA With PD1 Immunotherapy In Control Of Tumor Growth In Animal Model
Preprint of results from animal study shows restriction of tumor growth in mice treated with ZBTB46 mRNA nanoparticles based on Altamira's SemaPhore™ delivery technology
Nanoparticle treatment combined with
Despite Failed Phase 3 Study, FDA Staff Says Biogen’s ALS Drug May Have Clinical Benefit
FDA’s Peripheral and Central Nervous System Drugs Advisory Committee will virtually meet on Wednesday, March 22, to discuss Biogen Inc’s (NASDAQ:BIIB) ALS…
Why Enzo Biochem Stock Is Skyrocketing After Hours
Enzo Biochem Inc (NYSE: ENZ) shares are soaring in extended trading Thursday after the company agreed to sell its clinical lab to Laboratory Corporation Of America</
Roivant Sciences Highlights Topline Data From Atopic Dermatitis Drug In Patients As Young As 2 Years
Dermavant Sciences, a Roivant Sciences Ltd. (NASDAQ:ROIV) company, announced results from ADORING 2 Phase 3 study evaluating VTAMA (tapinarof) cream, 1% in…
Protagonist Therapeutics Touts Positive Data From Bone Marrow Disorder Study
Protagonist Therapeutics Inc (NASDAQ:PTGX) announced topline results from the blinded, placebo-controlled, randomized withdrawal portion of REVIVE of rusfertide for polycythemia vera,…
Why Jounce Therapeutics Stock Is Moving Higher Today?
The Board of Directors of Jounce Therapeutics Inc (NASDAQ:JNCE) confirmed that Concentra Biosciences LLC made an unsolicited and non-binding proposal to acquire 100%…